全文获取类型
收费全文 | 12231篇 |
免费 | 813篇 |
国内免费 | 93篇 |
专业分类
耳鼻咽喉 | 81篇 |
儿科学 | 273篇 |
妇产科学 | 222篇 |
基础医学 | 1448篇 |
口腔科学 | 286篇 |
临床医学 | 865篇 |
内科学 | 3296篇 |
皮肤病学 | 546篇 |
神经病学 | 618篇 |
特种医学 | 526篇 |
外科学 | 2156篇 |
综合类 | 42篇 |
一般理论 | 1篇 |
预防医学 | 283篇 |
眼科学 | 192篇 |
药学 | 733篇 |
中国医学 | 14篇 |
肿瘤学 | 1555篇 |
出版年
2023年 | 157篇 |
2022年 | 328篇 |
2021年 | 504篇 |
2020年 | 272篇 |
2019年 | 357篇 |
2018年 | 453篇 |
2017年 | 415篇 |
2016年 | 454篇 |
2015年 | 418篇 |
2014年 | 539篇 |
2013年 | 558篇 |
2012年 | 880篇 |
2011年 | 929篇 |
2010年 | 472篇 |
2009年 | 389篇 |
2008年 | 658篇 |
2007年 | 740篇 |
2006年 | 651篇 |
2005年 | 614篇 |
2004年 | 527篇 |
2003年 | 440篇 |
2002年 | 402篇 |
2001年 | 187篇 |
2000年 | 190篇 |
1999年 | 172篇 |
1998年 | 93篇 |
1997年 | 57篇 |
1996年 | 64篇 |
1995年 | 38篇 |
1994年 | 44篇 |
1993年 | 44篇 |
1992年 | 114篇 |
1991年 | 104篇 |
1990年 | 98篇 |
1989年 | 128篇 |
1988年 | 90篇 |
1987年 | 82篇 |
1986年 | 61篇 |
1985年 | 62篇 |
1984年 | 43篇 |
1983年 | 33篇 |
1979年 | 21篇 |
1978年 | 28篇 |
1977年 | 22篇 |
1976年 | 14篇 |
1975年 | 15篇 |
1973年 | 18篇 |
1970年 | 20篇 |
1968年 | 14篇 |
1966年 | 14篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
101.
Daisuke Tamanoi Koichi Saruwatari Kosuke Imamura Ryo Sato Takuya Jodai Shohei Hamada Yusuke Tomita Sho Saeki Shikiko Ueno Yuji Yonemura Hidenori Ichiyasu Takuro Sakagami 《Internal medicine (Tokyo, Japan)》2022,61(11):1731
The effect of radiotherapy during immunotherapy on immune-related adverse events (irAEs) is not fully understood. We herein report a 74-year-old woman diagnosed with lung adenocarcinoma with programmed death ligand 1 expression ≥50% and treated with pembrolizumab. She developed fatal immune thrombocytopenia associated with pembrolizumab immediately following radiotherapy. A flow cytometry analysis of peripheral blood detected an increased expression of programmed death-1 (PD-1) and Ki-67 in CD4+ and CD8+ T cells after radiotherapy, compared with pre-irradiation measurements. This case suggests that radiotherapy may evoke irAEs during treatment with anti-PD-1 antibodies, which physicians should consider when using radiotherapy in patients treated with these drugs. 相似文献
102.
Mao Hagihara Hideo Kato Toshie Sugano Hayato Okade Nobuo Sato Yuichi Shibata Daisuke Sakanashi Nobuhiro Asai Yusuke Koizumi Hiroyuki Suematsu Yuka Yamagishi Hiroshige Mikamo 《International journal of antimicrobial agents》2021,57(5):106330
BackgroundCarbapenem-resistant Enterobacterales (CRE) and carbapenemase-producing Enterobacterales (CPE) are difficult to treat and are a serious public health threat. Nacubactam (NAC) is a novel non-β-lactam diazabicyclooctane β-lactamase inhibitor with in vitro activity against some Enterobacterales expressing classes of β-lactamases.MethodsThe antimicrobial efficacy of meropenem (MEM), cefepime (FEP), and aztreonam (ATM), each in combination with NAC, were assessed in vitro and in vivo against Klebsiella pneumoniae and Escherichia coli. Ten isolates, including CRE and/or CPE with β-lactamase genes, were used in this study. The relationship between phenotype and in vivo efficacy was assessed in a murine neutropenic thigh-infection model. Efficacy was determined by the change in bacterial quantity.ResultsThe results of the in vitro study showed the minimum inhibitory concentrations of the combination of NAC with either MEM, FEP, or ATM in a 1:1 ratio were 2 to >128-fold lower than those of MEM, FEP, or ATM alone against CRE+ isolates. In addition, combinations of β-lactams and NAC administered in the murine thigh-infection model showed greater efficacy against CRE+/CPE+, CRE+/CPE-, and CRE-/CPE+ isolates harboring various β-lactamase genes (IMP-1, IMP-6, KPC, DHA-1, or OXA-48) compared with MEM, FEP, ATM, and NAC alone.ConclusionMEM, FEP, or ATM in combination with NAC showed potent in vivo antimicrobial activity in a murine thigh-infection model caused by K. pneumoniae and E. coli, including CRE and/or CPE isolates. These findings indicate that these combinations of β-lactams and NAC are potential candidates for the treatment of CRE and/or CPE infections. 相似文献
103.
Yuzo Deguchi Takatoshi Maeno Yuichi Hori Nobuyuki Hiruta Daisuke Sasai Yukihiro Sato 《Case reports in ophthalmology》2014,5(2):226-230
Introduction
To report a case in which intraocular silicone oil migrated into the upper eyelid and caused ptosis.Methods
A 65-year-old woman presented with proliferative vitreoretinopathy in the right eye. Vitrectomies, injection of silicone oil and encircling were performed. Two months after the last operation, swelling of her right eyelid occurred.Result
Magnetic resonance imaging revealed moisture in the palpebral fat tissue. We incised the bulbar conjunctiva and confirmed silicone oil leakage from the vitreous cavity through the scleral button hole of the encircling suture. Postoperatively, the right upper eyelid swelling decreased. Histopathologically, dense macrophage infiltration was seen in the palpebral tissues.Conclusions
We report a rare case with a postoperative complication caused by silicone oil. In cases with swelling of the eyelid and decreased silicon oil in the vitreous cavity postoperatively, clinicians should consider the possibility of silicone oil leakage.Key words: Migration of silicone oil, Upper eyelid, Vitrectomy, Scleral buckling, Postoperative complication, Ptosis 相似文献104.
105.
Daisuke Ueda Kosuke Niwa Hiroshi Nishikawa Yasuaki Tsuchida Keigo Yamashita 《Clinical Case Reports》2022,10(8)
A 71‐year‐old woman was admitted to the hospital due to cardiac tamponade. Computed tomography revealed that the diameter and wall thickness of the ascending aorta were 36 and 9 mm, respectively. An emergent ascending aortic replacement was performed uneventfully. The pathological findings indicated frank rupture of intramural hematoma. 相似文献
106.
107.
Kensei Yamaguchi Keiko Minashi Daisuke Sakai Tomohiro Nishina Yasushi Omuro Masahiro Tsuda Shiroh Iwagami Hisato Kawakami Taito Esaki Naotoshi Sugimoto Takashi Oshima Ken Kato Kenji Amagai Hisashi Hosaka Keigo Komine Hisateru Yasui Yuji Negoro Kenji Ishido Takahiro Tsushima Shirong Han Shinichi Shiratori Tomoko Takami Kohei Shitara 《Cancer science》2022,113(8):2814
The KEYNOTE‐659 study evaluated the efficacy and safety of first‐line pembrolizumab plus S‐1 and oxaliplatin (SOX) (cohort 1) or S‐1 and cisplatin (SP) (cohort 2) for advanced gastric/gastroesophageal junction (G/GEJ) cancer in Japan. Herein, we update the results of cohort 1 and describe the results of cohort 2. This open‐label phase IIb study enrolled patients with advanced programmed death‐ligand 1 (PD‐L1)‐positive (combined positive score ≥ 1) human epidermal growth factor receptor 2 (HER2)‐negative G/GEJ adenocarcinoma. The primary end‐point was the objective response rate (ORR). Other end‐points were duration of response (DOR), disease control rate (DCR), progression‐free survival (PFS), overall survival (OS), and safety. One hundred patients were enrolled. In cohorts 1 and 2, median follow‐up time was 16.9 and 17.1 months; ORR (central review), 72.2% and 80.4%; DOR, 10.6 and 9.5 months; DCR (central review), 96.3% and 97.8%; median PFS (central review), 9.4 and 8.3 months; and median OS, 16.9 and 17.1 months, respectively. Treatment‐related adverse events (TRAEs) occurred in all patients, including peripheral sensory neuropathy (94.4%, cohort 1), decreased neutrophil count (82.6%, cohort 2), nausea (59.3% and 60.9% in cohorts 1 and 2), and decreased appetite (61.1% and 60.9% in cohorts 1 and 2). Grade 3 or higher TRAEs were reported by 59.3% (cohort 1) and 78.3% (cohort 2), including decreased platelet count (14.8%, cohort 1) and decreased neutrophil count (52.2%, cohort 2). Pembrolizumab in combination with SOX or SP showed favorable efficacy and safety in patients with PD‐L1‐positive, HER2‐negative G/GEJ adenocarcinoma. 相似文献
108.
109.
Preclinical and first‐in‐human phase I studies of KW‐2450, an oral tyrosine kinase inhibitor with insulin‐like growth factor receptor‐1/insulin receptor selectivity 下载免费PDF全文
Gary K. Schwartz Mark A. Dickson Patricia M. LoRusso Edward A. Sausville Yoshimi Maekawa Yasuo Watanabe Naomi Kashima Daisuke Nakashima Shiro Akinaga 《Cancer science》2016,107(4):499-506
Numerous solid tumors overexpress or have excessively activated insulin‐like growth factor receptor‐1 (IGF‐1R). We summarize preclinical studies and the first‐in‐human study of KW‐2450, an oral tyrosine kinase inhibitor with IGF‐1R and insulin receptor (IR) inhibitory activity. Preclinical activity of KW‐2450 was evaluated in various in vitro and in vivo models. It was then evaluated in a phase I clinical trial in 13 patients with advanced solid tumors (NCT00921336). In vitro, KW‐2450 inhibited human IGF‐1R and IR kinases (IC50 7.39 and 5.64 nmol/L, respectively) and the growth of various human malignant cell lines. KW‐2450 40 mg/kg showed modest growth inhibitory activity and inhibited IGF‐1‐induced signal transduction in the murine HT‐29/GFP colon carcinoma xenograft model. The maximum tolerated dose of KW‐2450 was 37.5 mg once daily continuously; dose‐limiting toxicity occurred in two of six patients at 50 mg/day (both grade 3 hyperglycemia) and in one of seven patients at 37.5 mg/day (grade 3 rash). Four of 10 evaluable patients showed stable disease. Single‐agent KW‐2450 was associated with modest antitumor activity in heavily pretreated patients with solid tumors and is being further investigated in combination therapy with lapatinib/letrozole in patients with human epidermal growth factor receptor 2‐postive metastatic breast cancer. 相似文献
110.
Suzuki N Kameyama K Hirao T Susumu N Mukai M Aoki D 《The journal of obstetrics and gynaecology research》2007,33(2):203-206
Small cell carcinoma is a rare form of ovarian cancer with a poor prognosis. It is divided into two types, the hypercalcemic and the pulmonary type, of which the latter is extremely rare. A 49-year-old woman presented with an acute abdomen and was suspected to have torsion of a left ovarian tumor, which was followed up with an emergency operation. Postoperative pathological examination gave a diagnosis of the pulmonary type of ovarian small cell carcinoma. Six courses of paclitaxel and carboplatin therapy were given as adjuvant chemotherapy. The patient has survived for 36 months without recurrence. Here we present an extremely rare patient with the pulmonary type of ovarian small cell carcinoma. 相似文献